CD4 and neoplasm: Thus, targeting tumor-derived small EVs and their immunosuppressive cargo, such as cirmiR-20a-5p and PD-L1, presents a promising strategy to restore CD8 + and CD4 + T cell functionality and enhance anti-tumor immunity in TNBC (Table 1a).